Vamorolone
Orphan DrugFDA Approved
Contents
Description
Vamorolone is an oral dissociative corticosteroid approved for Duchenne muscular dystrophy. It was developed to preserve anti-inflammatory activity while potentially reducing some steroid-related toxicities, making it a differentiated specialty option in an orphan neuromuscular disease. Global access has expanded through multiple regulatory pathways outside the United States as well.
Indications & Therapeutic Use
Duchenne muscular dystrophy
Linked Diseases:
Duchenne Muscular Dystrophy
G71.01D020388
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Buy / Source Vamorolone — GNH India
6 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Vamorolone products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Vamorolone
| Generic Name | vamorolone |
| Brands | 1 brand available |
| Active Ingredient | vamorolone |
| Drug Class | Duchenne muscular dystrophy |
| Manufacturer | Santhera Pharmaceuticals |
| Dosage Forms | Oral suspension |
| Medical Code | H02AB |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT02760264 |
| Countries | 2 countries |
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes